Work

Nemo: a Phase 3 Trial of Binimetinib (Mek162) Versus Dacarbazine in Patients with Advanced Nras-Mutant Melanoma Who are Untreated or Have Progressed After Any Number of Immunotherapy Regimens

Year: 2014

Type: article

Source: Annals of Oncology

DOI: 10.1093/annonc/mdu344.46

Authors: R. Dummer, P. Arenberger, P.A. Ascierto, J.W. De Groot, S. Hallmeyer, M. Lotem, G.V. Long, M. Marples, D. Schadendorf, A.N. Starodub, M. Taylor, P. Wolter, N. Yamazaki, E. Wasserman, J. Ford, M. Weill, K.T. Flaherty

Institutions: University Hospital Zurich, Charles University, Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale", Isala, Oncology Specialists, Hadassah Medical Center, The University of Sydney, Melanoma Institute Australia, St James's University Hospital, Essen University Hospital, Stiftung Universitätsmedizin Essen, Indiana University Health, Oregon Health & Science University, Universitair Ziekenhuis Leuven, National Cancer Center Hospital, Novartis (United States), Massachusetts General Hospital

Language: English

Topic: Melanoma and MAPK Pathways

Subfield: Molecular Biology

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: bronze

OpenAlex ID: W2204001177

FWCI: 0.244

Cites:

Cited by: 7

Related to: 10